<DOC>
	<DOCNO>NCT01184287</DOCNO>
	<brief_summary>The purpose trial determine rate improvement objective tumor response , follow addition ranpirnase ongoing pemetrexed—carboplatin chemotherapy , patient SD PR follow 2 cycle doublet chemotherapy .</brief_summary>
	<brief_title>A Study Of Ranpirnase ( Onconase® ) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ranpirnase</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age great 18 year ECOG less 2 Estimated survival great 12 week Prior systemic chemotherapy locally advance metastatic NSCLC Use investigational agent within 28 day prior registration Known hypersensitivity study drug Brain metastasis leptomeningeal disease History prior malignancy within past three year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Non Small Cell Lung Cancer , NSCLC , Lung Cancer</keyword>
	<keyword>Previously untreated Non-Squamous , Non-Small Cell Lung Cancer</keyword>
</DOC>